Bartosz Puła

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak et al. · The Lancet Oncology · 2023 · 69 citations · Full text

Hematological Malignancy, Interim Analysis, Oncology +10

Outcomes of treatment with dose‐adjusted EPOCH‐R or R‐CHOP in primary mediastinal large B‐cell lymphoma

Agata Malenda, Agnieszka Kołkowska‐Leśniak, Bartosz Puła et al. · European Journal Of Haematology · 2019 · 37 citations · Full text

Surgical Oncology, Pathology, Surgery +16

A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia

Wojciech Czardybon, Renata Windak, Aniela Gołas et al. · Oncotarget · 2018 · 35 citations · Full text

Hematological Malignancy, Pim Inhibitors, Medicine +15

Comparison of metallothionein (MT) and Ki-67 antigen expression in benign and malignant thyroid tumours.

Anna Królicka, Christopher Kobierzycki, Bartosz Puła et al. · PubMed · 2010 · 28 citations

Tumor Biology, Endocrine Oncology, Ki-67 Antigen Expression +13

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Tadeusz Kubicki, Dominik Dytfeld, David R. Barnidge et al. · Blood · 2024 · 27 citations · Full text